A.B.K. Lahiru Dhananjaya
Research Subjects
A.B.K. Lahiru Dhananjaya has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- A. P. G. M. V. Samaraweera
University of Peradeniya, Kandy, Sri Lanka, Sri Lanka
1 shared publication - Shalika Parakatawella
Shizuoka University, Shizuoka, Japan, Japan
1 shared publication - U.M. Thisari Maleesha Gunathilaka
Shizuoka University, Shizuoka, Japan, Japan
1 shared publication
Latest Publications
- Open Access
- 7 July 2026
- Published by MDPI AG in Preprints.org
Toward Clinically Translatable Nanorobots for Cancer: Advances in Design Principles, Navigation Control, AI-Enabled Autonomy, and Post-Treatment Removal Strategies
Conventional systemic drug delivery often yields low efficacy and significant side effects due to off-target accumulation and rapid clearance. While nanoscale carriers leverage the enhanced permeability and retention (EPR) effect, this passive targeting is unreliable because tumor vascular heterogeneity leads to widely variable nanoparticle accumulation. As an alternative, untethered micro- and nanorobots (MNRs) have been engineered to actively navigate through complex fluids and autonomously deliver payloads to previously inaccessible sites. These autonomous biohybrids integrate nanoscale actuators, sensors, and computational units to enable precise, on-demand therapeutic actions at the cellular level. In particular, integrating artificial intelligence endows nanorobots with advanced sensing and decision-making capabilities: they can analyze molecular biomarkers and map biological pathways in real time to determine optimal treatment plans, yielding highly personalized, responsive therapies with enhanced efficacy. We also examine strategies for post-treatment removal of MNRs, emphasizing immune-compatible, biodegradable designs that allow metabolic clearance. This review aims to provide a comprehensive, in-depth, and nuanced examination of nanorobots in medical applications mainly in cancer treatments. Finally, we highlight remaining technical, manufacturing, regulatory and ethical challenges such as ensuring biocompatibility, scalable fabrication, and rigorous safety evaluation that must be ad-dressed for clinical translation.
- 7 July 2026
- Published by MDPI AG in Preprints.org
Open AccessToward Clinically Translatable Nanorobots for Cancer: Advances in Design Principles, Navigation Control, AI-Enabled Autonomy, and Post-Treatment Removal Strategies
Conventional systemic drug delivery often yields low efficacy and significant side effects due to off-target accumulation and rapid clearance. While nanoscale carriers leverage the enhanced permeability and retention (EPR) effect, this passive targeting is unreliable because tumor vascular heterogeneity leads to widely variable nanoparticle accumulation. As an alternative, untethered micro- and nanorobots (MNRs) have been engineered to actively navigate through complex fluids and autonomously deliver payloads to previously inaccessible sites. These autonomous biohybrids integrate nanoscale actuators, sensors, and computational units to enable precise, on-demand therapeutic actions at the cellular level. In particular, integrating artificial intelligence endows nanorobots with advanced sensing and decision-making capabilities: they can analyze molecular biomarkers and map biological pathways in real time to determine optimal treatment plans, yielding highly personalized, responsive therapies with enhanced efficacy. We also examine strategies for post-treatment removal of MNRs, emphasizing immune-compatible, biodegradable designs that allow metabolic clearance. This review aims to provide a comprehensive, in-depth, and nuanced examination of nanorobots in medical applications mainly in cancer treatments. Finally, we highlight remaining technical, manufacturing, regulatory and ethical challenges such as ensuring biocompatibility, scalable fabrication, and rigorous safety evaluation that must be ad-dressed for clinical translation.